Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Rituximab (MabThera) til behandling af aktiv reumatoid artritis

Research output: Contribution to journalJournal articleResearch

  1. The risks of selective serotonin reuptake inhibitor intake in pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hjernerystelse skal tages alvorligt

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Chimeric antigen receptor-T-cellebehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Terapeutisk cancervaccination mod hæmatologisk cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Perspektiver på recidiverende respiratorisk papillomatose og humant papillomvirus-vaccination

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Thyroid peroxidase antibodies and prospective live birth rate: A cohort study of women with recurrent pregnancy loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Statin treatment, oxidative stress and inflammation in a Danish population

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Eosinofili

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.
Translated title of the contribution[Rituximab (MabThera) as treatment of active rheumatoid arthritis]
Original languageDanish
JournalUgeskrift for Laeger
Volume168
Issue number47
Pages (from-to)4079-81
Number of pages3
Publication statusPublished - 20 Nov 2006

ID: 31052506